Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CD38 | P28907 | 6/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.46 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27937552 | 0.98 | KDM4E (0.54) | KDM4ETDP1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL15366752 | 0.90 | KDM4E (0.47) | KDM4ETDP1ALDH1A1SMN1; SMN2L3MBTL1 | |
| 2-Phenylphenol SCHEMBL15366864 | 0.85 | DHODH (0.48) | KDM4ETDP1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL30503376 | 0.83 | CD38 (0.48) | KDM4EALDH1A1SMN1; SMN2CYP1A2CD38 | |
| SCHEMBL30503380 | 0.81 | KDM4E (0.51) | KDM4EALDH1A1MEN1KMT2ACD38 | |
| SCHEMBL16832654 | 0.80 | KDM4E (0.62) | KDM4EALDH1A1SMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL8966258 | 0.76 | KDM4E (0.69) | KDM4ETDP1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL2873413 | 0.75 | KDM4E (0.62) | KDM4ETDP1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4299350 | 0.75 | KDM4E (0.62) | KDM4ETDP1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL30587187 | 0.75 | KDM4E (0.62) | KDM4ETDP1ALDH1A1SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11877506-B2 | Polycyclic aromatic compound | KWANSEI GAKUIN EDUCATIONAL FOUNDATION (JP) | 2024-01-16 | — | — | US | disclosed |
| US-20230276708-A1 | Polycyclic aromatic compound | KWANSEI GAKUIN EDUCATIONAL FOUNDATION (JP) | 2023-08-31 | — | — | US | disclosed |
| US-11711970-B2 | Organic electroluminescent device | KWANSEI GAKUIN EDUCATIONAL FOUNDATION (JP) | 2023-07-25 | — | — | US | disclosed |
| US-4186201-A | ANTIALLERGIC AGENTS | RIKER LABORATORIES, INC. (US) | 1980-01-29 | — | — | US | disclosed |
| US-4147694-A | ANTIALLERGENS, ANTIHISTAMINES | RIKER LABORATORIES, INC. (US) | 1979-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11877506-B2 | Polycyclic aromatic compound | F11, C1R, RNF31 | KDM4E 4253/4885TDP1 2533/4885ALDH1A1 2814/4885 |
| US-20230276708-A1 | Polycyclic aromatic compound | ACVR1B, XDH, AHR | KDM4E 583/4885TDP1 2715/4885ALDH1A1 2290/4885 |
| US-11711970-B2 | Organic electroluminescent device | LEF1, AOC2, AFF2 | KDM4E 1417/4885TDP1 705/4885ALDH1A1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.